These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Completed, but no date 2008-006369-10 Preliminary assessment of the clinical tolerability, safety and immunogenicity of three different doses of grass pollen-derived peptides for oral use in antigen-specific immunotherapy of seasonal alle... bad-data
Not reported 2010-023176-12 Clinical efficacy, immunogenicity, clinical tolerability and assessment of safety of gpASIT+TM administered orally, according to two administration schedules, for the prophylaxis of seasonal grass pol... 2012-01-04 due-trials
Completed, but no date Terminated 2011-004486-33 Safety, clinical tolerability and immunogenicity of gpASIT+TM administered subcutaneously to hay fever patients either alone or in presence of DnaK immunoregulating adjuvant. bad-data
Not reported 2013-000056-18 Safety, clinical tolerability and immunogenicity of increasing doses of gpASIT+TM administered subcutaneously to hay fever patients. A Phase IIa dose-escalation study. 2013-12-09 due-trials
Completed, but no date 2013-005445-37 A prospective, randomized, double-blind placebo-controlled multi-centre dose-finding study of 3 different regimens of gpASIT+TM administered subcutaneously to adult patients with grass pollen-induced ... bad-data
Not reported 2015-002105-11 A multicenter, international, randomised, double-blind, placebo controlled study to demonstrate the clinical efficacy and safety of a subcutaneous immunotherapy with gpASIT+™ in patients with grass po... 2016-09-15 due-trials
Not reported 2016-000557-13 Assessment of safety and clinical tolerability of hdmASIT+TM administered subcutaneously in house dust mite-induced allergic rhinoconjunctivitis patients. 2017-01-23 due-trials
Ongoing 2017-002911-33 A multicentre, international, randomised, double-blind, placebo controlled study to demonstrate the clinical efficacy and safety of subcutaneous immunotherapy with gpASIT+™ in patients with grass poll... not-yet-due
Exempt 2017-004616-19 A dose-ranging clinical study to determine the range of grass pollen allergen (gpCPT+) concentrations to be used in a conjunctival provocation test to grade moderate to severe grass pollen allergic rh... not-yet-due